BiotechTube

GSBR-1290 + Placebo

Phase 1/2Completed
1 views this week 0 watching💤 Quiet
Interest: 26/100
26
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Overweight or Obesity

Conditions

Overweight or Obesity, Type2 Diabetes Mellitus

Trial Timeline

Jan 9, 2023 → Apr 11, 2024

NCT ID
NCT05762471

About GSBR-1290 + Placebo

GSBR-1290 + Placebo is a phase 1/2 stage product being developed by Structure Therapeutics for Overweight or Obesity. The current trial status is completed. This product is registered under clinical trial identifier NCT05762471. Target conditions include Overweight or Obesity, Type2 Diabetes Mellitus.

What happened to similar drugs?

0 of 20 similar drugs in Overweight or Obesity were approved

Approved (0) Terminated (0) Active (20)
🔄Eloralintide + PlaceboEli LillyPhase 3
🔄Eloralintide + PlaceboEli LillyPhase 3
🔄Tirzepatide + PlaceboEli LillyPhase 3
🔄Tirzepatide + PlaceboEli LillyPhase 3
🔄Maridebart cafraglutide + PlaceboAmgenPhase 3
🔄Semaglutide + Semaglutide PlaceboNovo NordiskPhase 3
🔄Semaglutide + PlaceboNovo NordiskPhase 3

Hype Score Breakdown

Clinical
9
Activity
8
Company
9
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT05762471Phase 1/2Completed

Competing Products

20 competing products in Overweight or Obesity

See all competitors
ProductCompanyStageHype Score
TERN-601Terns PharmaceuticalsPhase 2
32
LY3457263 + Tirzepatide + PlaceboEli LillyPhase 1
29
LY3305677 + PlaceboEli LillyPhase 1
29
LY3537031 + PlaceboEli LillyPhase 1
33
Tirzepatide + Lisdexamfetamine Dimesylate + Placebo (oral) + Placebo (injection)Eli LillyPhase 2
42
Eloralintide + PlaceboEli LillyPhase 3
47
LY4064912 + LY4064912 + Placebo + PlaceboEli LillyPhase 1
36
LY3437943 + Ethinyl Estradiol + DrospirenoneEli LillyPhase 1
29
Tirzepatide + AcetaminophenEli LillyPhase 1
29
Tirzepatide + PlaceboEli LillyPhase 2
39
Eloralintide + PlaceboEli LillyPhase 3
47
LY3437943 + PlaceboEli LillyPhase 1
29
LY3502970 + PlaceboEli LillyPhase 1
29
Tirzepatide + PlaceboEli LillyPhase 3
44
Eloralintide and Tirzepatide + EloralintideEli LillyPhase 1
29
Tirzepatide + PlaceboEli LillyPhase 3
40
LY3541105 + PlaceboEli LillyPhase 1
29
Retatrutide + PlaceboEli LillyPhase 2
35
LY4167586 + Placebo + LY4167586Eli LillyPhase 1
36
AZD9550 + AZD6234 + Placebo comparatorAstraZenecaPhase 2
39